Vical Incorporated Stock Price, News & Analysis (NASDAQ:VICL)

$1.94 -0.02 (-1.02 %)
(As of 11/20/2017 04:28 AM ET)
Previous Close$1.96
Today's Range$1.94 - $2.01
52-Week Range$1.66 - $3.70
Volume306,900 shs
Average Volume173,702 shs
Market Capitalization$36.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94

About Vical Incorporated (NASDAQ:VICL)

Vical Incorporated logoVical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Sector: Medical
  • Symbol: NASDAQ:VICL
  • CUSIP: 92560210
  • Web: www.vical.com
Debt:
  • Current Ratio: 3.82%
  • Quick Ratio: 3.82%
Sales & Book Value:
  • Annual Sales: $14.53 million
  • Price / Sales: 1.68
  • Book Value: $4.08 per share
  • Price / Book: 0.48
Profitability:
  • Trailing EPS: ($1.07)
  • Net Income: ($8,970,000.00)
  • Net Margins: -92.13%
  • Return on Equity: -29.06%
  • Return on Assets: -23.52%
Misc:
  • Employees: 73
  • Outstanding Shares: 12,610,000
 

Frequently Asked Questions for Vical Incorporated (NASDAQ:VICL)

What is Vical Incorporated's stock symbol?

Vical Incorporated trades on the NASDAQ under the ticker symbol "VICL."

How were Vical Incorporated's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) released its quarterly earnings data on Monday, October, 23rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.02. The biotechnology company had revenue of $3.24 million for the quarter, compared to analyst estimates of $3.60 million. Vical Incorporated had a negative net margin of 92.13% and a negative return on equity of 29.06%. View Vical Incorporated's Earnings History.

When will Vical Incorporated make its next earnings announcement?

Vical Incorporated is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Vical Incorporated.

Where is Vical Incorporated's stock going? Where will Vical Incorporated's stock price be in 2017?

3 brokerages have issued 1-year target prices for Vical Incorporated's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Vical Incorporated's share price to reach $9.00 in the next twelve months. View Analyst Ratings for Vical Incorporated.

Who are some of Vical Incorporated's key competitors?

Who are Vical Incorporated's key executives?

Vical Incorporated's management team includes the folowing people:

  • R. Gordon Douglas M.D., Independent Chairman of the Board (Age 80)
  • Vijay B. Samant, President, Chief Executive Officer, Director (Age 63)
  • Anthony Alan Ramos, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer (Age 50)
  • Mammen P. Mammen Jr., Vice President - Clinical Vaccines (Age 51)
  • Lawrence Russell Smith, Vice President - Vaccine Research (Age 54)
  • Thomas E. Shenk Ph.D., Director
  • Richard M. Beleson, Independent Director (Age 61)
  • Gary A. Lyons, Independent Director (Age 66)
  • Robert C. Merton Ph.D., Independent Director (Age 70)
  • George J. Morrow, Independent Director (Age 64)

How do I buy Vical Incorporated stock?

Shares of Vical Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical Incorporated's stock price today?

One share of Vical Incorporated stock can currently be purchased for approximately $1.94.

How big of a company is Vical Incorporated?

Vical Incorporated has a market capitalization of $36.08 million and generates $14.53 million in revenue each year. The biotechnology company earns ($8,970,000.00) in net income (profit) each year or ($1.07) on an earnings per share basis. Vical Incorporated employs 73 workers across the globe.

How can I contact Vical Incorporated?

Vical Incorporated's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected]


MarketBeat Community Rating for Vical Incorporated (NASDAQ VICL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Vical Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Vical Incorporated (NASDAQ:VICL)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (363.92% upside)

Consensus Price Target History for Vical Incorporated (NASDAQ:VICL)

Price Target History for Vical Incorporated (NASDAQ:VICL)

Analysts' Ratings History for Vical Incorporated (NASDAQ:VICL)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Ifs SecuritiesReiterated RatingOutperformMediumView Rating Details
8/9/2017HC WainwrightSet Price TargetBuy$9.00LowView Rating Details
6/12/2017Rodman & RenshawReiterated RatingBuy -> Buy$9.00HighView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Vical Incorporated (NASDAQ:VICL)

Earnings by Quarter for Vical Incorporated (NASDAQ:VICL)

Earnings History by Quarter for Vical Incorporated (NASDAQ VICL)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018        
10/23/2017Q3 2017($0.25)($0.27)$3.60 million$3.24 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.28)($0.30)$3.35 million$3.42 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.18)($0.25)$3.21 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.21)($0.25)$2.92 million$3.16 millionViewListenView Earnings Details
11/3/2016Q3($0.25)($0.24)$4.60 million$2.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.28)($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.03)$6.88 million$4.60 millionViewN/AView Earnings Details
3/14/2016Q415($0.02)($0.03)$4.82 million$6.81 millionViewListenView Earnings Details
7/30/2015Q215($0.06)($0.03)$3.80 million$4.20 millionViewListenView Earnings Details
5/8/2015Q115($0.05)($0.04)$2.50 million$4.90 millionViewN/AView Earnings Details
2/26/2015Q414($0.05)($0.05)$3.58 million$4.82 millionViewN/AView Earnings Details
10/30/2014Q314($0.05)($0.05)$2.50 million$3.40 millionViewN/AView Earnings Details
7/31/2014Q214($0.05)($0.05)$1.90 million$4.50 millionViewN/AView Earnings Details
5/1/2014Q114($0.05)($0.04)$1.60 million$2.40 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)($0.03)$1.54 million$3.15 millionViewN/AView Earnings Details
10/31/2013Q313($0.10)($0.11)$1.82 million$1.50 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.11)($0.11)$1.70 million$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.11)($0.11)$2.02 million$1.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.10)($0.09)$1.64 million$2.32 millionViewN/AView Earnings Details
11/7/2012Q312($0.09)($0.09)$1.47 million$2.20 millionViewN/AView Earnings Details
8/1/2012($0.09)($0.09)ViewN/AView Earnings Details
11/1/2011$0.11$0.22ViewN/AView Earnings Details
8/3/2011($0.12)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vical Incorporated (NASDAQ:VICL)
Current Year EPS Consensus Estimate: $-1.07 EPS
Next Year EPS Consensus Estimate: $-1.08 EPS

Dividends

Dividend History for Vical Incorporated (NASDAQ:VICL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vical Incorporated (NASDAQ VICL)

Insider Ownership Percentage: 5.88%
Institutional Ownership Percentage: 20.30%
Insider Trades by Quarter for Vical Incorporated (NASDAQ:VICL)
Institutional Ownership by Quarter for Vical Incorporated (NASDAQ:VICL)

Insider Trades by Quarter for Vical Incorporated (NASDAQ VICL)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Robert C MertonDirectorBuy85,700$1.75$149,975.00View SEC Filing  
3/27/2017Anthony Alan RamosVPSell4,250$2.17$9,222.50View SEC Filing  
1/11/2017Lawrence Russell SmithVPSell54$2.48$133.92View SEC Filing  
1/10/2017Vijay B. SamantCEOSell5,763$2.45$14,119.35View SEC Filing  
12/22/2016Robert C. MertonDirectorSell4,000$2.24$8,960.00View SEC Filing  
12/20/2016Robert C. MertonDirectorSell4,327$2.21$9,562.67View SEC Filing  
12/13/2016Vijay B. SamantCEOSell15,699$2.39$37,520.61View SEC Filing  
12/12/2016R Gordon DouglasDirectorSell10,078$2.39$24,086.42View SEC Filing  
10/11/2016Lawrence Russell SmithVPSell54$3.05$164.70View SEC Filing  
7/11/2016Lawrence Russell SmithVPSell54$4.46$240.84View SEC Filing  
6/14/2016Robert C MertonDirectorBuy9,000$4.34$39,060.00View SEC Filing  
6/9/2016Vijay B SamantCEOBuy15,700$4.72$74,104.00View SEC Filing  
6/6/2016R Gordon DouglasDirectorBuy10,078$4.41$44,443.98View SEC Filing  
6/3/2016Gary A LyonsDirectorBuy7,078$4.39$31,072.42View SEC Filing  
3/15/2016Lawrence Russell SmithVPSell8,750$0.41$3,587.50View SEC Filing  
3/3/2016Vijay B SamantCEOSell37,500$0.36$13,500.00View SEC Filing  
2/19/2016Anthony Alan RamosCAOSell7,500$0.33$2,475.00View SEC Filing  
1/25/2016Anthony Alan RamosCAOSell193$0.35$67.55View SEC Filing  
1/12/2016Vijay B. SamantCEOSell59,737$0.35$20,907.95View SEC Filing  
1/11/2016Lawrence Russell SmithVPSell974$0.36$350.64View SEC Filing  
1/11/2016Vijay B. SamantCEOSell48,535$0.35$16,987.25View SEC Filing  
1/7/2016Vijay B SamantCEOSell75,000$0.36$27,000.00View SEC Filing  
10/12/2015Lawrence Russell SmithVPSell974$0.43$418.82View SEC Filing  
10/12/2015Vijay B SamantCEOSell4,738$0.41$1,942.58View SEC Filing  
7/13/2015Igor BilinskySVPSell1,258$0.70$880.60View SEC Filing  
7/13/2015Lawrence Russell SmithVPSell974$0.70$681.80View SEC Filing  
7/13/2015Vijay B SamantCEOSell4,737$0.70$3,315.90View SEC Filing  
4/13/2015Igor BilinskySVPSell1,257$0.93$1,169.01View SEC Filing  
4/13/2015Vijay B SamantCEOSell4,738$0.93$4,406.34View SEC Filing  
3/30/2015Vijay B SamantCEOSell55,000$0.91$50,050.00View SEC Filing  
1/13/2015Vijay B SamantCEOSell4,737$1.12$5,305.44View SEC Filing  
1/12/2015Igor BilinskySVPSell1,335$1.16$1,548.60View SEC Filing  
1/12/2015Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
10/13/2014Igor BilinskySVPSell1,335$1.08$1,441.80View SEC Filing  
10/13/2014Lawrence Russell SmithVPSell1,912$1.08$2,064.96View SEC Filing  
10/13/2014Vijay B SamantCEOSell4,738$1.13$5,353.94View SEC Filing  
8/26/2014Anthony Alan RamosCAOSell12,500$1.25$15,625.00View SEC Filing  
7/14/2014Vijay B SamantCEOSell4,737$1.17$5,542.29View SEC Filing  
7/11/2014Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
4/14/2014Vijay SamantCEOSell4,738$1.16$5,496.08View SEC Filing  
4/11/2014Lawrence Russell SmithVPSell1,912$1.21$2,313.52View SEC Filing  
1/10/2014Anthony Alan RamosCAOBuy70,000$1.42$99,400.00View SEC Filing  
1/10/2014Igor BilinskyVPBuy90,000$1.42$127,800.00View SEC Filing  
1/10/2014Vijay SamantCEOBuy330,000$1.42$468,600.00View SEC Filing  
9/12/2013James R SingerMajor ShareholderSell200,000$1.29$258,000.00View SEC Filing  
9/11/2013James R SingerMajor ShareholderSell300,000$1.30$390,000.00View SEC Filing  
9/10/2013James R SingerMajor ShareholderSell200,000$1.23$246,000.00View SEC Filing  
9/9/2013James R SingerMajor ShareholderSell200,000$1.22$244,000.00View SEC Filing  
9/4/2013James Singermajor shareholderSell466,000$1.24$577,840.00View SEC Filing  
8/30/2013James Singermajor shareholderSell84,000$1.31$110,040.00View SEC Filing  
8/29/2013James Singermajor shareholderSell150,000$1.30$195,000.00View SEC Filing  
8/28/2013James Singermajor shareholderSell200,000$1.31$262,000.00View SEC Filing  
8/26/2013Anthony Alan RamosCAOBuy25,000$0.01$250.00View SEC Filing  
5/23/2013Robert C MertonDirectorBuy5,953$0.01$59.53View SEC Filing  
1/11/2013Alain P Phd RollandVPBuy22,092$0.01$220.92View SEC Filing  
1/11/2013Jill Marie BroadfootCFOBuy27,060$0.01$270.60View SEC Filing  
1/11/2013Vijay B SamantCEOBuy84,600$0.01$846.00View SEC Filing  
10/15/2012George J MorrowDirectorBuy6,394$0.01$63.94View SEC Filing  
9/24/2012James R SingerMajor ShareholderBuy154,333$3.99$615,788.67View SEC Filing  
8/31/2012James R SingerMajor ShareholderBuy310,000$3.51$1,088,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vical Incorporated (NASDAQ VICL)

Source:
DateHeadline
Vical Incorporated (VICL) Director Acquires $149,975.00 in StockVical Incorporated (VICL) Director Acquires $149,975.00 in Stock
www.americanbankingnews.com - November 14 at 1:32 PM
Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common StockVical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock
finance.yahoo.com - November 9 at 9:29 AM
32 Stocks Moving In Wednesdays Pre-Market Session32 Stocks Moving In Wednesday's Pre-Market Session
feeds.benzinga.com - November 8 at 8:50 AM
ETFs with exposure to Vical, Inc. : November 6, 2017ETFs with exposure to Vical, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 1:00 PM
Reviewing Vical (VICL) & Its PeersReviewing Vical (VICL) & Its Peers
www.americanbankingnews.com - October 26 at 9:20 PM
ETFs with exposure to Vical, Inc. : October 26, 2017ETFs with exposure to Vical, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 11:58 AM
Vical Incorporated (VICL) Downgraded to "Sell" at Zacks Investment ResearchVical Incorporated (VICL) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 26 at 9:00 AM
Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017
finance.yahoo.com - October 25 at 4:00 PM
Vical Incorporateds (VICL) CEO Vijay Samant on Q3 2017 Results - Earnings Call TranscriptVical Incorporated's (VICL) CEO Vijay Samant on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 24 at 4:13 PM
Vical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B InfectionVical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B Infection
finance.yahoo.com - October 24 at 11:59 AM
Edited Transcript of VICL earnings conference call or presentation 23-Oct-17 4:00pm GMTEdited Transcript of VICL earnings conference call or presentation 23-Oct-17 4:00pm GMT
finance.yahoo.com - October 24 at 11:59 AM
Vical teams up with AnGes to develop new HBV treatment; shares ahead 7% premarketVical teams up with AnGes to develop new HBV treatment; shares ahead 7% premarket
seekingalpha.com - October 24 at 8:26 AM
Vical Reports Third Quarter 2017 Financial and Operational ResultsVical Reports Third Quarter 2017 Financial and Operational Results
finance.yahoo.com - October 23 at 8:52 AM
Vical reports 3Q lossVical reports 3Q loss
finance.yahoo.com - October 23 at 8:52 AM
Vical Incorporated (VICL) Set to Announce Quarterly Earnings on MondayVical Incorporated (VICL) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 18 at 10:28 AM
Vical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial ResultsVical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial Results
feeds.benzinga.com - October 16 at 5:56 PM
Vical to Provide Company Update at BIO Investor Forum ConferenceVical to Provide Company Update at BIO Investor Forum Conference
finance.yahoo.com - October 14 at 9:11 AM
Vical (VICL) Reports Completion of the Phase 3 ASP0113 CMV Vaccine TrialVical (VICL) Reports Completion of the Phase 3 ASP0113 CMV Vaccine Trial
www.streetinsider.com - October 12 at 2:50 AM
Vical completes the Phase 3 ASP0113 CMV vaccine trial; shares up 14% premarketVical completes the Phase 3 ASP0113 CMV vaccine trial; shares up 14% premarket
seekingalpha.com - October 12 at 2:50 AM
ETFs with exposure to Vical, Inc. : October 11, 2017ETFs with exposure to Vical, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 4:47 PM
Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine TrialVical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial
finance.yahoo.com - October 10 at 8:08 AM
Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy TrialVical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial
finance.yahoo.com - October 3 at 2:28 PM
Mid-stage study may suffice under LUI for Vicals antifungal VL-2397; shares ahead 37% after hoursMid-stage study may suffice under LUI for Vical's antifungal VL-2397; shares ahead 37% after hours
seekingalpha.com - October 2 at 5:42 PM
Vical to Present at IDWeek and the 8th Trends in Medical Mycology ConferencesVical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences
globenewswire.com - September 28 at 9:23 AM
ETFs with exposure to Vical, Inc. : September 14, 2017ETFs with exposure to Vical, Inc. : September 14, 2017
finance.yahoo.com - September 15 at 10:59 AM
Vical (VICL) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowVical (VICL) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 10:27 PM
Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 13 at 3:53 PM
Vical to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceVical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 7 at 10:47 AM
Vical Incorporated (NASDAQ:VICL) Stock Rating Reaffirmed by Ifs SecuritiesVical Incorporated (NASDAQ:VICL) Stock Rating Reaffirmed by Ifs Securities
www.americanbankingnews.com - August 11 at 4:00 PM
Investor Network Invites You to the Vical Second Quarter 2017 Earnings Webcast Live on Tuesday, August 8, 2017Investor Network Invites You to the Vical Second Quarter 2017 Earnings Webcast Live on Tuesday, August 8, 2017
finance.yahoo.com - August 10 at 9:23 AM
Edited Transcript of VICL earnings conference call or presentation 8-Aug-17 4:00pm GMTEdited Transcript of VICL earnings conference call or presentation 8-Aug-17 4:00pm GMT
finance.yahoo.com - August 10 at 9:23 AM
Vical Incorporateds (VICL) CEO Vijay Samant on Q2 2017 Results - Earnings Call TranscriptVical Incorporated's (VICL) CEO Vijay Samant on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 8:55 AM
Vical Incorporated (VICL) Posts  Earnings Results, Misses Estimates By $0.02 EPSVical Incorporated (VICL) Posts Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 8 at 2:40 PM
Vical Reports Second Quarter 2017 Financial and Operational ResultsVical Reports Second Quarter 2017 Financial and Operational Results
finance.yahoo.com - August 8 at 8:04 AM
Vical reports 2Q lossVical reports 2Q loss
finance.yahoo.com - August 8 at 8:04 AM
Vical Incorporated (VICL) to Release Quarterly Earnings on TuesdayVical Incorporated (VICL) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 12:06 PM
Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial ResultsVical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 8:25 AM
ETFs with exposure to Vical, Inc. : June 30, 2017ETFs with exposure to Vical, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 8:46 AM
Vical to Present VL-2397 Data at the June ASM Microbe 2017 MeetingVical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
feeds.benzinga.com - May 23 at 7:09 AM
Vical misses by $0.07, misses on revenueVical misses by $0.07, misses on revenue
seekingalpha.com - May 15 at 6:43 AM
Vical revenues off 30% in Q1Vical revenues off 30% in Q1
seekingalpha.com - May 15 at 6:43 AM
Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial ResultsVical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
feeds.benzinga.com - May 8 at 7:07 AM
Vical (VICL) Finalizes Target Enrollment for Phase 2 Therapeutic HSV-2 Vaccine TrialVical (VICL) Finalizes Target Enrollment for Phase 2 Therapeutic HSV-2 Vaccine Trial
www.streetinsider.com - April 21 at 12:07 AM
VICAL INC Files SEC form 10-K, Annual ReportVICAL INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 11 at 10:10 AM
Vicals (VICL) CEO Vijay Samant on Q4 2016 Results - Earnings Call TranscriptVical's (VICL) CEO Vijay Samant on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 10 at 9:57 AM
Vical to Provide Company Update at the 29th Annual ROTH ConferenceVical to Provide Company Update at the 29th Annual ROTH Conference
feeds.benzinga.com - March 10 at 7:27 AM
Vical Reports Fourth Quarter 2016 Financial ResultsVical Reports Fourth Quarter 2016 Financial Results
us.rd.yahoo.com - March 9 at 11:17 PM
Q4 2016 Vical Inc Earnings Release - Before Market OpenQ4 2016 Vical Inc Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 11:17 PM
VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsVICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 9 at 11:17 PM
Vical misses by $0.04, misses on revenueVical misses by $0.04, misses on revenue
seekingalpha.com - March 9 at 6:49 AM

Social Media

Financials

Chart

Vical Incorporated (NASDAQ VICL) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.